Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status

0371265 - ÚMG 2012 RIV GB eng J - Článek v odborném periodiku
Šímová, Jana - Polláková, Veronika - Indrová, Marie - Mikyšková, Romana - Bieblová, Jana - Štěpánek, Ivan - Bubeník, Jan - Reiniš, Milan
Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status.
British Journal of Cancer. Roč. 105, č. 10 (2011), s. 1533-1541. ISSN 0007-0920. E-ISSN 1532-1827
Grant CEP: GA ČR GA301/07/1410; GA ČR GAP301/10/2174; GA ČR GA301/09/1024
GRANT EU: European Commission(XE) 18933 - CLINIGENE
Výzkumný záměr: CEZ:AV0Z50520514
Klíčová slova: 5-azacytidine * MHC class I downregulation * tumour chemoimmunotherapy
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 5.042, rok: 2011

We evaluated the anti-tumour effects of the DNA methyltransferase inhibitor 5-azacytidine (5AC) The 5AC therapy was combined with immunotherapy, using a murine model for HPV16-associated tumours. We have demonstrated 5AC additive effects against MHC class I-positive and -deficient tumours when combined with unmethylated CpG oligodeoxynucleotides (CpG ODN) or with IL-12-producing cellular vaccine. The efficacy of the combined chemoimmunotherapy against originally MHC class I-deficient tumours was partially dependent on the CD8+-mediated immune responses. Increased cell surface expression of MHC class I cell molecules, associated with upregulation of the antigen-presenting machinery-related genes, as well as of genes encoding selected components of the IFNγ signalling pathway in tumours explanted from 5AC-treated animals, were observed.
Trvalý link: http://hdl.handle.net/11104/0204817